Journal article

Association between adult height, genetic susceptibility and risk of glioma

Cari M Kitahara, Sophia S Wang, Beatrice S Melin, Zhaoming Wang, Melissa Braganza, Peter D Inskip, Demetrius Albanes, Ulrika Andersson, Laura E Beane Freeman, Julie E Buring, Tania Carreon, Maria Feychting, Susan M Gapstur, J Michael Gaziano, Graham G Giles, Goran Hallmans, Susan E Hankinson, Roger Henriksson, Ann W Hsing, Christoffer Johansen Show all



BACKGROUND: Some, but not all, observational studies have suggested that taller stature is associated with a significant increased risk of glioma. In a pooled analysis of observational studies, we investigated the strength and consistency of this association, overall and for major sub-types, and investigated effect modification by genetic susceptibility to the disease. METHODS: We standardized and combined individual-level data on 1354 cases and 4734 control subjects from 13 prospective and 2 case-control studies. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) for glioma and glioma sub-types were estimated using logistic regression models stratified by sex and adjusted for birth..

View full abstract


Awarded by National Cancer Institute

Awarded by National Institute of Environmental Health Sciences

Awarded by National Institutes of Health

Awarded by Australian National Health and Medical Research Council

Awarded by NCI


Funding Acknowledgements

This work was supported in part by the Intramural Research Program of the NCI, National Institutes of Health.For CPS-II Nutrition Cohort: The Cancer Prevention Studies are supported by the American Cancer Society. Efforts of the ACS the study management group to maintain and follow the cohort are acknowledged. ACS investigators also acknowledge the contributions from central cancer registries supported through the Centers for Disease Control and Prevention's National Program of Cancer Registries and cancer registries supported by the National Cancer Institute's Surveillance Epidemiology and End Results Program.For NYUWHS: The NYUWHS is supported by National Cancer Institute grants R01 CA098661 and P30 CA016087 and by Center grant ES000260 from the National Institute of Environmental Health Sciences.For PHS: The PHS is supported by grants CA 97193, CA 34944, CA 40360, HL 26490, and HL 34595 from the National Institutes of Health.For CLUE: Cancer incidence data were provided by the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Department of Health and Mental Hygiene, 201 W. Preston Street, Room 400, Baltimore, MD 21201, USA;, 410-767-4055. The authors acknowledge the State of Maryland, the Maryland Cigarette Restitution Fund and the National Program of Cancer Registries of the Centers for Disease Control and Prevention for the funds that support the collection and availability of the cancer registry data. The findings and conclusions of this report are those of the authors and do not necessarily represent the views of the Maryland Cancer Registry.For PLCO: This research was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and by contracts from the Division of Cancer Prevention, NCI, National Institutes of Health (NIH) and Department of Health and Human Services (DHHS). The authors thank Drs Christine Berg and Philip Prorok, Division of Cancer Prevention, NCI, the Screening Center investigators and staff of the PLCO cancer screening trial, Mr Tom Riley and staff, Information Management Services, Inc., Ms Barbara O'Brien and staff, Westat, Inc., Mr Tim Sheehy and staff, DNA Extraction and Staging Laboratory, SAIC-Frederick, Inc. and Ms Jackie King and staff, BioReliance, Inc.For MCCS: Infrastructure support for the MCCS recruitment and follow-up is provided by the Cancer Council Victoria, and cohort recruitment was partly funded by VicHealth. This work using the MCCS was supported by the Australian National Health and Medical Research Council (grant numbers 209057, 251533 and 396414).For VITAL: Grant K05CA154337 is funded by the NCI and the NIH Office of Dietary Supplements (ODS).